Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.50 |
| ▸ | CYP11B1 | P15538 | 10/20 | 0.48 |
| ▸ | CYP11B2 | P19099 | 10/20 | 0.48 |
| ▸ | ECE1 | P42892 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | HPGDS | O60760 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | LDHA | P00338 | 1/20 | 0.45 |
| ▸ | WNT3A | P56704 | 2/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8228375 | 1.00 | BAZ2B (0.50) | BAZ2BCYP11B1CYP11B2ECE1CYP3A4 | |
| SCHEMBL12568331 | 0.88 | AURKA (0.47) | BAZ2BCYP11B1CYP11B2ECE1NPC1 | |
| SCHEMBL12568317 | 0.88 | ACACB (0.44) | BAZ2BCYP11B1CYP11B2ECE1NPC1 | |
| SCHEMBL12568338 | 0.87 | NPC1 (0.42) | BAZ2BCYP11B1CYP11B2ECE1NPC1 | |
| SCHEMBL12568350 | 0.86 | RXFP1 (0.50) | CYP11B1CYP11B2NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL12568322 | 0.86 | CYP11B1 (0.43) | CYP11B1CYP11B2ECE1CYP3A4WNT3A | |
| SCHEMBL12568329 | 0.85 | CYP11B1 (0.40) | BAZ2BCYP11B1CYP11B2ECE1CYP3A4 | |
| SCHEMBL12568330 | 0.85 | ATR (0.44) | ECE1NPC1RAB9ASMN1; SMN2TP53 | |
| SCHEMBL12568334 | 0.85 | FYN (0.41) | ECE1CYP3A4NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL12568321 | 0.85 | PPARA (0.47) | CYP11B1CYP11B2ECE1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7960349-B2 | N-terminally modified GLP-1 receptor modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-06-14 | — | — | US | disclosed |
| US-7960349-B2 | N-terminally modified GLP-1 receptor modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-06-14 | — | — | US | disclosed |
| US-20100022457-A1 | Sustained release glp-1 receptor modulators | BRISTOL-MYERS SQUIBB COMPANY | 2010-01-28 | — | — | US | disclosed |
| US-20100022457-A1 | Sustained release glp-1 receptor modulators | BRISTOL-MYERS SQUIBB COMPANY | 2010-01-28 | — | — | US | disclosed |
| US-7534763-B2 | Sustained release GLP-1 receptor modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-05-19 | — | — | US | disclosed |
| US-7534763-B2 | Sustained release GLP-1 receptor modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-05-19 | — | — | US | disclosed |
| US-20080242593-A1 | HUMAN GLUCAGON-LIKE-PEPTIDE-1 MODULATORS AND THEIR USE IN THE TREATMENT OF DIABETES AND RELATED CONDITIONS | BRISTOL-MYERS SQUIBB COMPANY | 2008-10-02 | — | — | US | disclosed |
| US-20080242593-A1 | HUMAN GLUCAGON-LIKE-PEPTIDE-1 MODULATORS AND THEIR USE IN THE TREATMENT OF DIABETES AND RELATED CONDITIONS | BRISTOL-MYERS SQUIBB COMPANY | 2008-10-02 | — | — | US | disclosed |
| US-7417028-B2 | Human glucagon-like-peptide-1 modulators and their use in treatment of diabetes and related conditions | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-08-26 | — | — | US | disclosed |
| US-7417028-B2 | Human glucagon-like-peptide-1 modulators and their use in treatment of diabetes and related conditions | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-08-26 | — | — | US | disclosed |
| US-20080045461-A1 | N-TERMINALLY MODIFIED GLP-1 RECEPTOR MODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2008-02-21 | — | — | US | disclosed |
| US-20080045461-A1 | N-TERMINALLY MODIFIED GLP-1 RECEPTOR MODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2008-02-21 | — | — | US | disclosed |
| WO-2007139589-A1 | SUSTAINED RELEASE GLP-1 RECEPTOR MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-12-06 | — | — | WO | disclosed |
| US-20070099835-A1 | Sustained release GLP-1 receptor modulators | BRISTOL-MYERS SQUIBB COMPANY | 2007-05-03 | — | — | US | disclosed |
| US-20070099835-A1 | Sustained release GLP-1 receptor modulators | BRISTOL-MYERS SQUIBB COMPANY | 2007-05-03 | — | — | US | disclosed |
| US-20070021346-A1 | N-terminally modified GLP-1 receptor modulators | BRISTOL-MYERS SQUIBB COMPANY | 2007-01-25 | — | — | US | disclosed |
| US-20070021346-A1 | N-terminally modified GLP-1 receptor modulators | BRISTOL-MYERS SQUIBB COMPANY | 2007-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070021346-A1 | N-terminally modified GLP-1 receptor modulators | GLP1R, GIPR, IAPP | BAZ2B 2187/4885CYP11B1 3426/4885CYP11B2 3592/4885 |
| US-20080242593-A1 | HUMAN GLUCAGON-LIKE-PEPTIDE-1 MODULATORS AND THEIR USE IN THE TREATMENT OF DIABETES AND RELATED CONDITIONS | GLP1R, GIPR, IAPP | BAZ2B 2554/4885CYP11B1 2200/4885CYP11B2 2507/4885 |
| US-20100022457-A1 | Sustained release glp-1 receptor modulators | GLP1R, GIPR, GRPR | BAZ2B 3720/4885CYP11B1 3739/4885CYP11B2 4191/4885 |
| US-20080045461-A1 | N-TERMINALLY MODIFIED GLP-1 RECEPTOR MODULATORS | GLP1R, GIPR, IAPP | BAZ2B 2097/4885CYP11B1 3416/4885CYP11B2 3565/4885 |
| US-20070099835-A1 | Sustained release GLP-1 receptor modulators | GLP1R, GIPR, GRPR | BAZ2B 3720/4885CYP11B1 3739/4885CYP11B2 4191/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.